抗HER-2治疗的耐药机制及对策的研究进展  

The research progress on the resistance mechanism of anti-HER-2 therapy

作　　者：吕晓双 罗斌[1] LYU Xiaoshuang;LUO Bin(Department of General Surgery,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218,China)

机构地区：[1]清华大学附属北京清华长庚医院普通外科,清华大学临床医学院,北京102218

出　　处：《现代肿瘤医学》2022年第3期529-534,共6页Journal of Modern Oncology

基　　金：北京市卫生系统高层次卫生技术人才培养计划(编号:2013-2-032)。

摘　　要：乳腺癌是女性最常见的恶性肿瘤,在女性癌症死亡原因中排名第二。约20%的乳腺癌为HER-2阳性乳腺癌。自从曲妥珠单抗、帕妥珠单抗、拉帕替尼、T-DM1等抗HER-2靶向治疗药物陆续问世后,HER-2阳性乳腺癌的预后显著提升,7年无疾病生存(DFS)提升可达95%。然而很多患者,特别是晚期患者在接受抗HER-2治疗的过程中最终都会产生耐药,导致疾病进展。本文主要从分子机制方面来解释抗HER-2治疗的耐药情况,包括HER-2的结合障碍、HER-2信号通路的改变及免疫逃逸等方面,并介绍了可能解决耐药途径的研究进展。Breast cancer is the most common malignancy in women and ranks the second cause of cancer death in women.Furthermore,about 20%of breast cancers are HER-2-positive.Since trastuzumab,pertuzumab,lapatinib,T-DM1 and other anti-HER-2 targeted therapies emerged,the prognosis of HER-2-positive breast cancer has been improved significantly,and 7-year DFS has achieved to 95%.However,patients with advanced breast cancer will eventually develop resistance during the course of receiving anti-HER-2 therapy,leading to progression of the disease.This article mainly explains the drug resistance of anti-HER-2 therapy with regard to the molecular mechanisms,including HER-2 binding barriers,alterations in the HER-2 signaling pathways and immune escape,meantime introduces recent scientific progress that may solve the drug resistance.

关 键 词：人表皮生长因子受体-2 分子靶向治疗 肿瘤免疫逃逸 肿瘤疫苗 

分 类 号：R730.53[医药卫生—肿瘤]